ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.069
Day Range
$0.069 – $0.069
52 Week Range
$0.052 – $0.155
Volume
0.00
Avg Volume (10D)
98.18K
Price Chart
OHLC · volume · moving averages
$0.069-$0.051 (-42.50%)over 6M
Hi$0.140Lo$0.052Avg Vol248.9K
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$0.069
Previous Close
$0.069
Day High
$0.069
Day Low
$0.069
52 Week High
$0.155
52 Week Low
$0.052
Valuation
Fundamental multiples
Market Cap
0.00
Shares Outstanding
0.00
Price to Book
9.58
Trading Activity
Volume & order book
Volume
0.00
Value Traded
0.00
Bid
$0.066 × 48,965
Ask
$0.070 × 56,210
Performance
Returns across timeframes
1 Day
-1.52%
5 Day
25.00%
13 Week
-16.67%
52 Week
0.00%
YTD
-38.10%
Technical Indicators
Momentum & moving averages
RSI (14)
57.75
50-Day SMA
$0.068
200-Day SMA
$0.091
— From the desk
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.